Hydroxyurea
規格
127-07-1CAS番号
204-821-7EC番号
hydroxyureaIUPAC名
CH4N2O2化学式
76.055 g/mol分子量
hydroxyurea; 127-07-1; Hydroxycarbamide; N-Hydroxyurea; Hydrea; Oxyurea; Carbamoyl oxime; Biosupressin; Carbamohydroxamic acid; Carbamohydroximic acid; Litalir; Hydroxycarbamine; Urea, hydroxy-; Onco-carbide; Droxia; Hidrix; Hydura; Carbamyl hydroxamate; Hydurea; N-Carbamoylhydroxylamine; Siklos; Hydroxicarbamidum; Hydroxylurea; Hidroxicarbamida; Xromi; Hydroxyharnstoff; Hydroxycarbamidum; N-Hydroxymocovina; Carbamohydroxyamic acid; SQ 1089; Hydroxylamine, N-carbamoyl-; Hydroxycarbamid; Oncocarbide; Idrossicarbamide; Hydroxylamine, N-(aminocarbonyl)-; SK 22591; NCI-C04831; NSC 32065; NSC-32065; DTXSID6025438; SQ-1089; AI3-51139; NSC32065; X6Q56QN5QC; DTXCID405438; CHEBI:44423; 4-03-00-00170 (Beilstein Handbook Reference); idroxicarbamide; Oxeron; Syrea; RefChem:389055; L01XX05; WR 83799; 204-821-7; 1-HYDROXYUREA; urea, N-hydroxy-; Hydreia; Litaler; Idrossicarbamide [DCIT]; hydroxy urea; Hydroxyharnstoff [German]; N-Hydroxymocovina [Czech]; Ichthammol; Hydroxycarbamidum [INN-Latin]; Hidroxicarbamida [INN-Spanish]; HU; CCRIS 958; HYDROXY-UREA; MFCD00007943; N-(Aminocarbonyl)hydroxylamine; 8029-68-3; CH4N2O2; Hydroxyurea (Cytodrox); Hydroxycarbamide [INN]; CHEMBL467; s1896; NCGC00015520-03; NHY; Hydroxyurea (D4); N-HYDROXY UREA; Mylocel; carbamide oxide; CAS-127-07-1; SMR000059149; Hydroxyurea (USP); Droxia (TM); Droxia (TN); Hydrea (TM); hydroxyaminomethanamide; HSDB 6887; SR-01000075919; DRG-0253; EINECS 204-821-7; HYDREA (TN); Hydroxyurea [USAN:USP]; UNII-X6Q56QN5QC; BRN 1741548; Hydroxycarbamide (JAN/INN); hydroxyl urea; S-phase/G-1 interface inhibitor; aminohydroxamic acid; carbamic acid oxime; Hydroxycarbamide CRS; Siklos (TN); IL-6 & Hydroxyurea; Spectrum_000909; WLN: ZVMQ; Hydrea (Bristol Meyers); Hydroxy Urea Impurity 2; HYDROXYUREA [MI]; Spectrum2_000064; Spectrum3_000462; Spectrum4_000012; Spectrum5_000836; Ammonium-bitumen-sulfonate; Lopac-H-8627; HYDROXYUREA [HSDB]; HYDROXYUREA [IARC]; HYDROXYUREA [USAN]; MolMap_000029; H 8627; HYDROXYUREA [VANDF]; NCIMech_000139; Hydroxyurea, 98%, powder; SCHEMBL4004; Lopac0_000596; BSPBio_002164; HYDROXYUREA [USP-RS]; KBioGR_000383; KBioSS_001389; MLS001332381; MLS001332382; MLS002153389; DivK1c_000556; HYDROXYCARBAMIDE [JAN]; SPECTRUM1500344; SPBio_000247; GTPL6822; orb1226631; orb1310395; SCHEMBL1503487; SCHEMBL2945292; SCHEMBL3456366; HYDROXYCARBAMIDE [MART.]; SCHEMBL31177136; tetratogen: inhibits ribonucleoside diphosphate reductase; HMS501L18; KBio1_000556; KBio2_001389; KBio2_003957; KBio2_006525; KBio3_001384; HYDROXYCARBAMIDE [WHO-DD]; HYDROXYUREA [ORANGE BOOK]; NINDS_000556; Bio1_000451; Bio1_000940; Bio1_001429; HMS1920F09; HMS2091L17; HMS2234I03; HMS3261H14; HMS3373G18; HMS3655K20; HMS3869C03; HMS5080E21; NCI C04831; Pharmakon1600-01500344; HYDROXYCARBAMIDE [EMA EPAR]; HYDROXYUREA [USP MONOGRAPH]; ichthyol, ichthammol, PSSO, DSSO; ALBB-028465; HY-B0313; STR02555; Tox21_110168; Tox21_300319; Tox21_500596; BBL009928; BDBM50017811; CCG-35236; EBC-03024; MSK163509; NSC757072; STL145898; AKOS005716276; AKOS006222547; Tox21_110168_1; DB01005; FH09735; HYDROXYCARBAMIDE [EP MONOGRAPH]; LP00596; NSC-757072; SDCCGSBI-0050578.P006; IDI1_000556; NCGC00015520-01; NCGC00015520-02; NCGC00015520-04; NCGC00015520-05; NCGC00015520-06; NCGC00015520-07; NCGC00015520-08; NCGC00015520-09; NCGC00015520-10; NCGC00015520-11; NCGC00015520-16; NCGC00015520-20; NCGC00093974-01; NCGC00093974-02; NCGC00093974-03; NCGC00093974-04; NCGC00093974-05; NCGC00254007-01; NCGC00261281-01; AC-22674; NCI60_002773; SBI-0050578.P004; DB-041849; EU-0100596; H0310; H9715; NS00002419; SW218071-2; EN300-82775; A10546; C07044; D00341; Hydroxyurea, Vetec(TM) reagent grade, >=98%; AB00052018-09; AB00052018-10; AB00052018_11; AB00052018_12; F043351; Q212272; SR-01000075919-1; SR-01000075919-3; SR-01000075919-8; BRD-K51747290-001-12-3; BRD-K51747290-001-13-1; BRD-K51747290-001-15-6; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; F8880-0905; Z1203577934; Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard; Hydroxyurea, United States Pharmacopeia (USP) Reference Standard別名
Hydroxyureaを含む製品
제일히드록시우레아캡슐(수출용)하이드린캡슐250밀리그램(히드록시우레아)히드레아캡슐(히드록시우레아)(수출용)[수출명:Hydroxyurea Cap. 500mg, Hydra Cap., DHNP Hydroxyurea Cap.]유니온히드록시우레아캡슐(수출용)(수출명:Uniroxy Cap. Gemini Hydroxyurea Cap.)하이드린캡슐500밀리그램(히드록시우레아)(수출명:GindreaCaps.500mg,KrabinexCaps.,HytinonCaps.)ハイドレアカプセル500mgSIKLOS 1.000 MG COMPRIMIDOS RECUBIERTOS CON PELICULASIKLOS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAHYDREA 500 mg CAPSULAS DURASHIDROXICARBAMIDA MEDAC 500 MG CÁPSULAS DURASHIDROXICARBAMIDA HIKMA 500 MG CAPSULAS DURAS EFGSIKLOS 1000 mg, comprimé pelliculé sécable
1/4ページ
Hydroxyureaを販売する企業
한국
한국유나이티드제약(주)Republic of KoreaHD
Hangzhou Dingyan Chem Co., LtdChina1/3ページ